KRAS and non-small cell lung carcinoma: Among all patients with stage IV or recurrent, metastatic KRAS G12C mutant NSCLC (n = 201 with KRAS G12C confirmed prior to first line systemic therapy), the median first-line rwPFS was 9.3 months (95% CI, 7.3–11.8 months) and median OS was 16.8 months (95% CI, 12.7–22.3 months).